NRG1 and cancer: Of note, in tumor models harboring NRG1 fusions, seribantumab leads to reduced phosphorylation across the ERBB family and subsequent inhibition of downstream signaling pathways, including the phosphoinositide 3-kinase protein kinase B and mitogen-activated protein kinase pathways, resulting in the inhibition of cancer cell survival [9].